Characterization of the “frequent exacerbator phenotype” in bronchiectasis

James D. Chalmers, Stefano Aliberti, Anna Filonenko, Michal Shteinberg, Pieter C. Goeminne, Adam T. Hill, Thomas C. Fardon, Dusanka Obradovic, Christoph Gerlinger, Giovanni Sotgiu, Elisabeth Operschall, Robert M. Rutherford, Katerina Dimakou, Eva Polverino, Anthony De Soyza, Melissa J. McDonnell

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Rationale: Exacerbations are key events in the natural history of bronchiectasis, but clinical predictors and outcomes of patients with frequently exacerbating disease are not well described. Objectives: To establish if there is a “frequent exacerbator phenotype” in bronchiectasis and the impact of exacerbations on long-term clinical outcomes. Methods: We studied patients with bronchiectasis enrolled from 10 clinical centers in Europe and Israel, with up to 5 years of follow-up. Patients were categorized by baseline exacerbation frequency (zero, one, two, or three or more per year). The repeatability of exacerbation status was assessed, as well as the independent impact of exacerbation history on hospitalizations, quality of life, and mortality. Measurements and Main Results: A total of 2,572 patients were included. Frequent exacerbations were the strongest predictor of future exacerbation frequency, suggesting a consistent phenotype.

The incident rate ratios for future exacerbations were 1.73 (95% confidence interval [CI], 1.47-2.02; P, 0.0001) for one exacerbation per year, 3.14 (95% CI, 2.70-3.66; P, 0.0001) for two exacerbations, and 5.97 (95% CI, 5.27-6.78; P, 0.0001) for patients with three or more exacerbations per year at baseline. Additional independent predictors of future exacerbation frequency were Haemophilus influenzae and Pseudomonas aeruginosa infection, FEV1, radiological severity of disease, and coexisting chronic obstructive pulmonary disease. Patients with frequently exacerbating disease had worse quality of life and were more likely to be hospitalized during followup. Mortality over up to 5 years of follow-up increased with increasing exacerbation frequency. Conclusions: The frequent exacerbator phenotype in bronchiectasis is consistent over time and shows high disease severity, poor quality of life, and increased mortality during follow-up.

Original languageEnglish
Pages (from-to)1410-1420
Number of pages11
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume197
Issue number11
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Bronchiectasis
Phenotype
Quality of Life
Confidence Intervals
Mortality
Pseudomonas Infections
Haemophilus influenzae
Israel
Pseudomonas aeruginosa
Chronic Obstructive Pulmonary Disease
Hospitalization
History

Keywords

  • Antibiotics
  • Bronchiectasis
  • Exacerbations
  • Infection
  • Mortality

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Chalmers, J. D., Aliberti, S., Filonenko, A., Shteinberg, M., Goeminne, P. C., Hill, A. T., ... McDonnell, M. J. (2018). Characterization of the “frequent exacerbator phenotype” in bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 197(11), 1410-1420. https://doi.org/10.1164/rccm.201711-2202OC

Characterization of the “frequent exacerbator phenotype” in bronchiectasis. / Chalmers, James D.; Aliberti, Stefano; Filonenko, Anna; Shteinberg, Michal; Goeminne, Pieter C.; Hill, Adam T.; Fardon, Thomas C.; Obradovic, Dusanka; Gerlinger, Christoph; Sotgiu, Giovanni; Operschall, Elisabeth; Rutherford, Robert M.; Dimakou, Katerina; Polverino, Eva; De Soyza, Anthony; McDonnell, Melissa J.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 197, No. 11, 01.06.2018, p. 1410-1420.

Research output: Contribution to journalArticle

Chalmers, JD, Aliberti, S, Filonenko, A, Shteinberg, M, Goeminne, PC, Hill, AT, Fardon, TC, Obradovic, D, Gerlinger, C, Sotgiu, G, Operschall, E, Rutherford, RM, Dimakou, K, Polverino, E, De Soyza, A & McDonnell, MJ 2018, 'Characterization of the “frequent exacerbator phenotype” in bronchiectasis', American Journal of Respiratory and Critical Care Medicine, vol. 197, no. 11, pp. 1410-1420. https://doi.org/10.1164/rccm.201711-2202OC
Chalmers, James D. ; Aliberti, Stefano ; Filonenko, Anna ; Shteinberg, Michal ; Goeminne, Pieter C. ; Hill, Adam T. ; Fardon, Thomas C. ; Obradovic, Dusanka ; Gerlinger, Christoph ; Sotgiu, Giovanni ; Operschall, Elisabeth ; Rutherford, Robert M. ; Dimakou, Katerina ; Polverino, Eva ; De Soyza, Anthony ; McDonnell, Melissa J. / Characterization of the “frequent exacerbator phenotype” in bronchiectasis. In: American Journal of Respiratory and Critical Care Medicine. 2018 ; Vol. 197, No. 11. pp. 1410-1420.
@article{dc9171ff54994144bc4c97ba107e1cec,
title = "Characterization of the “frequent exacerbator phenotype” in bronchiectasis",
abstract = "Rationale: Exacerbations are key events in the natural history of bronchiectasis, but clinical predictors and outcomes of patients with frequently exacerbating disease are not well described. Objectives: To establish if there is a “frequent exacerbator phenotype” in bronchiectasis and the impact of exacerbations on long-term clinical outcomes. Methods: We studied patients with bronchiectasis enrolled from 10 clinical centers in Europe and Israel, with up to 5 years of follow-up. Patients were categorized by baseline exacerbation frequency (zero, one, two, or three or more per year). The repeatability of exacerbation status was assessed, as well as the independent impact of exacerbation history on hospitalizations, quality of life, and mortality. Measurements and Main Results: A total of 2,572 patients were included. Frequent exacerbations were the strongest predictor of future exacerbation frequency, suggesting a consistent phenotype.The incident rate ratios for future exacerbations were 1.73 (95{\%} confidence interval [CI], 1.47-2.02; P, 0.0001) for one exacerbation per year, 3.14 (95{\%} CI, 2.70-3.66; P, 0.0001) for two exacerbations, and 5.97 (95{\%} CI, 5.27-6.78; P, 0.0001) for patients with three or more exacerbations per year at baseline. Additional independent predictors of future exacerbation frequency were Haemophilus influenzae and Pseudomonas aeruginosa infection, FEV1, radiological severity of disease, and coexisting chronic obstructive pulmonary disease. Patients with frequently exacerbating disease had worse quality of life and were more likely to be hospitalized during followup. Mortality over up to 5 years of follow-up increased with increasing exacerbation frequency. Conclusions: The frequent exacerbator phenotype in bronchiectasis is consistent over time and shows high disease severity, poor quality of life, and increased mortality during follow-up.",
keywords = "Antibiotics, Bronchiectasis, Exacerbations, Infection, Mortality",
author = "Chalmers, {James D.} and Stefano Aliberti and Anna Filonenko and Michal Shteinberg and Goeminne, {Pieter C.} and Hill, {Adam T.} and Fardon, {Thomas C.} and Dusanka Obradovic and Christoph Gerlinger and Giovanni Sotgiu and Elisabeth Operschall and Rutherford, {Robert M.} and Katerina Dimakou and Eva Polverino and {De Soyza}, Anthony and McDonnell, {Melissa J.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1164/rccm.201711-2202OC",
language = "English",
volume = "197",
pages = "1410--1420",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society - AJRCCM",
number = "11",

}

TY - JOUR

T1 - Characterization of the “frequent exacerbator phenotype” in bronchiectasis

AU - Chalmers, James D.

AU - Aliberti, Stefano

AU - Filonenko, Anna

AU - Shteinberg, Michal

AU - Goeminne, Pieter C.

AU - Hill, Adam T.

AU - Fardon, Thomas C.

AU - Obradovic, Dusanka

AU - Gerlinger, Christoph

AU - Sotgiu, Giovanni

AU - Operschall, Elisabeth

AU - Rutherford, Robert M.

AU - Dimakou, Katerina

AU - Polverino, Eva

AU - De Soyza, Anthony

AU - McDonnell, Melissa J.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Rationale: Exacerbations are key events in the natural history of bronchiectasis, but clinical predictors and outcomes of patients with frequently exacerbating disease are not well described. Objectives: To establish if there is a “frequent exacerbator phenotype” in bronchiectasis and the impact of exacerbations on long-term clinical outcomes. Methods: We studied patients with bronchiectasis enrolled from 10 clinical centers in Europe and Israel, with up to 5 years of follow-up. Patients were categorized by baseline exacerbation frequency (zero, one, two, or three or more per year). The repeatability of exacerbation status was assessed, as well as the independent impact of exacerbation history on hospitalizations, quality of life, and mortality. Measurements and Main Results: A total of 2,572 patients were included. Frequent exacerbations were the strongest predictor of future exacerbation frequency, suggesting a consistent phenotype.The incident rate ratios for future exacerbations were 1.73 (95% confidence interval [CI], 1.47-2.02; P, 0.0001) for one exacerbation per year, 3.14 (95% CI, 2.70-3.66; P, 0.0001) for two exacerbations, and 5.97 (95% CI, 5.27-6.78; P, 0.0001) for patients with three or more exacerbations per year at baseline. Additional independent predictors of future exacerbation frequency were Haemophilus influenzae and Pseudomonas aeruginosa infection, FEV1, radiological severity of disease, and coexisting chronic obstructive pulmonary disease. Patients with frequently exacerbating disease had worse quality of life and were more likely to be hospitalized during followup. Mortality over up to 5 years of follow-up increased with increasing exacerbation frequency. Conclusions: The frequent exacerbator phenotype in bronchiectasis is consistent over time and shows high disease severity, poor quality of life, and increased mortality during follow-up.

AB - Rationale: Exacerbations are key events in the natural history of bronchiectasis, but clinical predictors and outcomes of patients with frequently exacerbating disease are not well described. Objectives: To establish if there is a “frequent exacerbator phenotype” in bronchiectasis and the impact of exacerbations on long-term clinical outcomes. Methods: We studied patients with bronchiectasis enrolled from 10 clinical centers in Europe and Israel, with up to 5 years of follow-up. Patients were categorized by baseline exacerbation frequency (zero, one, two, or three or more per year). The repeatability of exacerbation status was assessed, as well as the independent impact of exacerbation history on hospitalizations, quality of life, and mortality. Measurements and Main Results: A total of 2,572 patients were included. Frequent exacerbations were the strongest predictor of future exacerbation frequency, suggesting a consistent phenotype.The incident rate ratios for future exacerbations were 1.73 (95% confidence interval [CI], 1.47-2.02; P, 0.0001) for one exacerbation per year, 3.14 (95% CI, 2.70-3.66; P, 0.0001) for two exacerbations, and 5.97 (95% CI, 5.27-6.78; P, 0.0001) for patients with three or more exacerbations per year at baseline. Additional independent predictors of future exacerbation frequency were Haemophilus influenzae and Pseudomonas aeruginosa infection, FEV1, radiological severity of disease, and coexisting chronic obstructive pulmonary disease. Patients with frequently exacerbating disease had worse quality of life and were more likely to be hospitalized during followup. Mortality over up to 5 years of follow-up increased with increasing exacerbation frequency. Conclusions: The frequent exacerbator phenotype in bronchiectasis is consistent over time and shows high disease severity, poor quality of life, and increased mortality during follow-up.

KW - Antibiotics

KW - Bronchiectasis

KW - Exacerbations

KW - Infection

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85048118422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048118422&partnerID=8YFLogxK

U2 - 10.1164/rccm.201711-2202OC

DO - 10.1164/rccm.201711-2202OC

M3 - Article

AN - SCOPUS:85048118422

VL - 197

SP - 1410

EP - 1420

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 11

ER -